Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | NPY4R | P50391 | 10/20 | 0.33 |
| ▸ | NPY1R | P25929 | 7/20 | 0.33 |
| ▸ | NPY2R | P49146 | 5/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7158448 | 1.00 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL18822222 | 1.00 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL16138483 | 0.94 | MEN1 (0.43) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7877053 | 0.84 | DPP7 (0.34) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL19368433 | 0.82 | DPP7 (0.33) | DPP7RRM1 | |
| SCHEMBL29404058 | 0.82 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20822004 | 0.82 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL26614349 | 0.82 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL6545309 | 0.82 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL21973636 | 0.81 | NPY4R (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017075505-A2 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075522-A2 | GLP-2 POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2017-05-04 | — | — | WO | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| US-9034814-B2 | CXCR4 antagonists for wound healing and re-epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-19 | — | — | US | disclosed |
| US-9034814-B2 | CXCR4 antagonists for wound healing and re-epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-19 | — | — | US | disclosed |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | disclosed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | disclosed |
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2009-07-16 | — | — | US | disclosed |
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2009-07-16 | — | — | US | disclosed |
| US-7423007-B2 | Cxcr4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2008-09-09 | — | — | US | disclosed |
| US-7423007-B2 | Cxcr4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2008-09-09 | — | — | US | disclosed |
| WO-2008075369-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075371-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | MEN1 4364/4885CYP1A2 4821/4885KMT2A 4599/4885 |
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | CXCR4, ACKR3, CXCR1 | MEN1 2827/4885CYP1A2 4715/4885KMT2A 1987/4885 |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | CXCR5, CXCR4, CXCR1 | MEN1 2469/4885CYP1A2 4866/4885KMT2A 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.